Drug Profile
Taletrectinib - AnHeart Therapeutics
Alternative Names: AB-106; DS-6051; DS-6051a; DS-6051b; IBI-344Latest Information Update: 17 Apr 2024
Price :
$50
*
At a glance
- Originator Daiichi Sankyo Inc
- Developer AnHeart Therapeutics; Daiichi Sankyo Inc; Innovent Biologics
- Class Amines; Antineoplastics; Fluorobenzenes; Heterocyclic bicyclo compounds; Imidazoles; Phenyl ethers; Pyridazines; Small molecules
- Mechanism of Action ROS1 protein inhibitors; TrkA receptor antagonists; TrkB receptor antagonists; TrkC receptor antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes
Highest Development Phases
- Preregistration Non-small cell lung cancer
- Phase III Solid tumours
Most Recent Events
- 10 Apr 2024 AnHeart Therapeutics has been acquired by Nuvation Bio
- 05 Mar 2024 Preregistration for Non-small cell lung cancer (First-line therapy, Late-stage disease, Metastatic disease) in China (PO)
- 20 Dec 2023 Taletrectinib receives priority review status for Non-small cell lung cancer (late-stage disease, Metastatic disease, Second-line therapy or greater) in China